Tuesday, April 22, 2025
HomeNewsDocprime Technologies invests $7.5 mn in Visit Health

Docprime Technologies invests $7.5 mn in Visit Health

Docprime Technologies, a unit of PB Fintech Ltd., which also owns Policybazaar and Paisabazaar, announced on Monday that it has invested $7.5 million in Visit Health, a telehealth and wellness platform.

Docprime has made its first investment in a complete telehealth and wellness platform.

Visit Health, which has been around for five years, offers an integrated solution that allows businesses to provide their employees with access to certified specialists while also guiding them in managing their healthcare needs. The technology enables businesses to improve their employees’ healthcare experiences while also reducing medical costs.

According to PB Fintech, the investment would help it improve its service capabilities in the health and wellness industry.

“Our goal with this investment is to back Visit Health in their vision to build a strong Digital Health Ecosystem – with outstanding customer service and new ways to help customers navigate a healthcare system. We are proud to back Visit as they approach their next phase of growth,” said Yashish Dahiya, chairman and chief executive officer, PB Fintech.

Docprime, the parent company of Policybazaar, launched its platform in August 2018 and allows customers to make appointments with doctors and diagnostic labs. The platform also serves as an agent, or a facilitator, for several healthcare, wellness, and personal care products.

“Visit is excited to have PB Fintech as a partner in our strategic vision to create a Digital Health Ecosystem. Our product offering is backed by Health insurers and the large cashless network stitched by us. With this investment, we plan to grow our platform and network capabilities and expand our teams across technology, sales, and network functions,” said Visit Health’s chief executive officer, Anurag Prasad on the acquisition.

Visit Health previously raised $1.4 million in a seed round and is backed by Snapdeal founders Kunal Bahl and Rohit Bansal and Hetero Drugs Director Murali Krishna. 

Biz Stone, the co-founder of Twitter, invested in the startup in 2018.

Subscribe To Newsletter

ICYMI

BRL Editor
BRL Editorhttps://businessreviewlive.com
Business Review Live covers finance, technology, travel, lifestyle, and everything in between through exclusive interviews and analysis, market statistics, digital video, and an expanded array of content formats.